top of page
I am a scientist and entrepreneur who has driven human therapeutics from idea...
... to Series A
Get It Here
Proof of Concept
Get It Here
Technical Strategy
Get It Here
Business Strategy
Get It Here
Early-stage Operations
Get It Here
Idea
Scientific literature
As seen in:
Press
"The potential applications of RCas9 are seemingly boundless."
"Such an approach has the potential to be applied to diverse transcript types in multiple cell systems"
.png)
.png)
Anchor 1
Scientific literature
As seen in:
Press
"Researchers [have used] CRISPR to fix problems in RNA rather than to change DNA, a promising step for a group of diseases, including Huntington’s and amyotrophic lateral sclerosis, that have no cure."
Proof of concept
Anchor 2
Anchor 3
Technical strategy
Business strategy
Early-stage operations
Experience
Co-founder and Chief Technology Officer at Locana, Inc.
Awards
STAT Wunderkind: selected during a nationwide search for "the next generation of scientific superstars"
BIOCOM Catalyst: among 15 awardees to have made unique contributions to the biotech community in Southern California
Press
"Locana bags $55M for RNA-targeting gene therapies"
"Locana, Fueled With $55M, Looks to Develop Fixes for Faulty RNA"
Series A
Anchor 4
Preclinical development
Published preclinical studies
As seen in:
Co-first author of a series of preclinical studies that establish the safety and efficacy of RNA-targeting Cas9 in a model of the most common type of adult-onset muscular dystrophy.
bottom of page